UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2024

Commission File Number: 001-37891

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F

On June 20, 2024, AC Immune SA ("**AC Immune**") held its Annual General Meeting of Shareholders. Part 1 includes the final results of the voting on the agenda items and Part 2 includes an operational update. The Management presentation to shareholders is attached hereto as Exhibit 99.1. Prior to the meeting, the board of directors of AC Immune withdrew agenda items 6.1, 6.2 and 6.3. The amended Articles of Association will be published on AC Immune's website (https://ir.acimmune.com/governance) after the filing of the document with the Swiss Register of Commerce. The final results of the remaining agenda items submitted to a vote of the shareholders are as below and the detailed results will be provided in the minutes which will be published on AC Immune's website (https://ir.acimmune.com/governance) within 15 days:

Part 1: Annual General Meeting Results

Agenda Item 1: 2023 IFRS Consolidated Financial Statements, 2023 Statutory Financial Statements and 2023 Compensation Report

Agenda Item 1.1: Approval of 2023 IFRS Consolidated Financial Statements and 2023 Statutory Financial Statements

AC Immune shareholders approved the 2023 IFRS Consolidated Financial Statements and the 2023 Statutory Financial Statements.

Agenda Item 1.2: Advisory Vote on the 2023 Compensation Report

AC Immune shareholders endorsed the 2023 Compensation Report.

Agenda Item 2: Appropriation of Losses

AC Immune shareholders approved that the net loss for the year 2023 in the amount of CHF 48,883K increases the "accumulated losses brought forward" of CHF 262,115K, resulting in a new balance of "accumulated losses brought forward" of CHF 310,998K.

Agenda Item 3: Discharge of the Board of Directors and of the Executive Committee

AC Immune shareholders approved the discharge of the members of the Board of Directors and of the Executive Committee for the financial year 2023.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2024 to the AGM 2025

AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 883K (excluding employer social security contributions) covering the period from the AGM 2024 to the AGM 2025.

Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2025

AC Immune shareholders approved the total maximum compensation for the members of the Executive Committee of CHF 7,605K (excluding employer social security contributions) from 1 January 2025 to 31 December 2025.

Agenda Item 5: Re-elections

Agenda Item 5.1: Re-elections of Members of the Board of Directors

AC Immune shareholders approved the re-election of Douglas Williams as member and as Chair of the Board of Directors and the re-election of Monika Bütler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman as members of the Board of Directors, each until the end of the Annual General Meeting 2025.

Agenda Item 5.2: Re-elections of Members of the Compensation, Nomination and Corporate Governance Committee

AC Immune shareholders approved the re-election of Monika Bütler, Roy Twyman and Douglas Williams as members of the Compensation, Nomination and Corporate Governance Committee, each until the end of the Annual General Meeting 2025.

Agenda Item 5.3: Re-election of the Statutory Auditors

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Pully, Switzerland, as AC Immune's statutory auditors for the financial year 2024.

Agenda Item 5.4: Re-election of the Independent Proxy

AC Immune shareholders approved the re-election of Reymond & Associés, Lausanne, as AC Immune's independent proxy until the end of the Annual General Meeting 2025.

Agenda Item 6: Changes in the Articles of Association

Agenda Item 6.4: Other changes

AC Immune shareholders approved an amendment to the second paragraph of article 8 (Powers), article 9 (Ordinary General Meeting), article 10 (Extraordinary General Meeting), article 11 (Notice and Agenda of Shareholders' Meeting), article 12 (Documentation), article 15 (Minutes), the second and third paragraphs of article 17 (Resolution and Elections), the second, third and fourth paragraphs of article 18 (Votes on Compensation), article 21 (Constitution), article 23 (Powers), article 26 (Meetings, Resolutions and Minutes), the first, third and fifth paragraphs of article 29 (Indemnification), article 30 (Election, Term), the second paragraph of article 32 (Principles of the Compensation of the Board of Directors), article 37 (Mandates of a Member of the Board of Directors outside the Company), article 38 (Mandates of a Member of the Executive Committee outside the Company), article 39 (Loans and Credits), article 41 (Options and Share Plans), the second paragraph of article 46 (Notices and Publications) and article 47 (Transitional Provisions concerning the Compensation of the Executive Committee) of the articles of association.

Part 2: Operational Update

The Company also provided an update that it is adjusting the timelines and communication plan for reporting data from the ongoing ABATE Phase 1b/2 trial following the recent exclusive option and license agreement related to ACI-24.060. AC Immune is currently developing the required joint practices with its partner for data sharing and communication, in accordance with the agreement and will communicate updated guidance on data reporting in Q3 2024.

The ongoing adaptive design ABATE study is a randomized, double-blind, placebo-controlled Phase 1b/2 trial (NCT05462106) assessing the safety, tolerability, immunogenicity and pharmacodynamic effects of the investigational immunotherapy in at least three dose cohorts of subjects with prodromal Alzheimer's disease (AD) and in individuals with Down syndrome (DS) between the ages of 35 and 50. Following data safety monitoring board (DSMB) reviews, no safety concerns, including no observations of amyloid-related imaging abnormalities (ARIA-E), have been raised to date, consistent with previous results.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By: /s/ Andrea Pfeifer
Name: Andrea Pfeifer
Title: Chief Executive Officer

By: /s/ Christopher Roberts
Name: Christopher Roberts
Title: Chief Financial Officer

Date: June 20, 2024

EXHIBIT INDEX

Exhibit Number	Description
99.1	Annual General Meeting presentation

Exhibit 99.1

Investor Update

NASDAQ: ACIU | Annual General Meeting – June 20, 2024

AC Immune

Disclaimer

This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CH, CN, GB, JP, KR, NO and RU.

Agenda

1. AC Immune's approach to neurodegenerative diseases
2. Business strategy and pipeline update
3. Clinical-stage active immunotherapy programs
4. Achievements and key milestones 2023/24
5. Financial figures
6. Summary and Strategic outlook

1. AC Immune's approach to neurodegenerative diseases



AC Immune at a glance

Pioneering new ways to treat neurodegenerative diseases

Broad, diverse pipeline – 16 programs
1 Phase 3 program and 5 in Phase 2

Key differentiation: Precision Medicine
Enables leadership in targeted therapies

Multiple global partnerships
>CHF 4.3 billion in potential milestones

Clinically validated technology platforms
Best-in-class small molecules and biologics

Cash reserves on Balance sheet
Funding into 2027[3]

- Based in Lausanne, Switzerland
- ~150 employees
- Listed September 2016 (NASDAQ: ACIU)
- 99.4 million shares outstanding[1]
- Cash of CHF 104.8 million[2] plus $100 million upfront from Takeda

Takeda
janssen PHARMACEUTICAL COMPANIES OF Johnson & Johnson
Lilly
Life HEALTH CARE Molecular Imaging

(1) As of March 31, 2024; excluding treasury shares; (2) as of March 31, 2024; (3) assumes second ACI-35-related milestone payment of CHF25 million received in 2025 and no other milestones

2. Business strategy and pipeline update



Broad and robust pipeline in neurodegenerative diseases

Driven by validated proprietary technology platforms for sustained growth

Clinical Stage Programs



(1) Alzheimer's disease; (2) Down syndrome-related Alzheimer's disease; (3) Refers to expected readouts from the ABATE Phase 1b/2 trial of ACI-24.060 in patients with AD; (4) alpha-synuclein; (5) Parkinson's disease; (6) Positron emission tomography; (7) Progressive supranuclear palsy; (8) ACI-12589, a-syn PET tracer for MSA; (9) Multiple system atrophy; (10) ACI-15916, a-syn PET tracer for PD

AC Immune technology platforms driving validating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform		
Unpartnered Programs	■ a-syn active immunotherapy ■ Anti-TDP-43 mAb[1] ■ Anti-NLRP3-ASC mAb	■ Mor-a-syn ■ Mor-TDP-43 PET ■ Mor-NLRP3-ASC

■ Considerable additional potential value in our unpartnered clinical and preclinical programs

(1) Monoclonal antibody

3. Clinical-stage active immunotherapy programs

ACTIVE Immune Therapy



ACTIVE Immune Therapy

targeting neurodegenerative diseases

Major advantages

- Long-lasting specific immunity for pathological target, consistent, boostable, durable
- Limited annual dosing (once or twice) after priming year
- No observed ARIA-E[1] to date (safety profile well suited to long-term use)
- Cost-effective (attractive healthcare economics across global populations)
- Improved access (ease of administration, simple logistics)



Active immunotherapy

Stimulates the patient's immune system to produce their own antibodies

Passive immunotherapy

Externally generated mAb requires administration every two to four weeks



ACTIVE Immune Therapy

ACI-24.060: Anti-Abeta for Alzheimer's disease



Landmark deal for ACI-24.060 in Alzheimer's disease

Supports promise of active immunization for neurodegenerative diseases

- The deal with Takeda covers AC Immune's unique, class-leading Abeta targeted active immunotherapy ACI-24.060

- Deal terms:
  - $100 million upfront payment received for exclusive option to license global rights
  - Option exercise fee in the low-to-mid nine-figure range linked to ABATE clinical data
  - Up to approximately $2.1 billion in potential payments including option exercise fee and development, commercial and sales-based milestones
  - Royalties in the mid-to-high teens on global sales

- Combines AC Immune's leadership in developing products for NDDs[1] with Takeda's clinical development expertise and history of driving neuroscience innovation

(1) Neurodegenerative diseases

ABATE: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD[1] and DS[2]

Placebo-controlled Phase 1b/2 Study Overview

Adaptive Study Design

Both	▪ Interim analyses of safety/tolerability & immunogenicity ▪ Biomarker analyses including Abeta PET[3] and others
AD	▪ Up to 4 different doses and/or dose regimens ▪ Expansion of one cohort to assess effect on Abeta PET
DS	▪ Initiation using selected dose identified in AD (based on safety/tolerability and immunogenicity)

Outcome measures

Both	▪ Safety/tolerability ▪ Pharmacodynamics: Serum anti-Abeta antibody titers ▪ Abeta-PET imaging ▪ Exploratory biomarkers and clinical endpoints

Trial Schematic



(1) Alzheimer's disease; (2) Down syndrome-related AD; (3) Positron emission tomography; (4) AD participants must between 50 – 85 years of age and have prodromal AD with Clinical Dementia Rating Global Score of 0.5 and Abeta pathology confirmed by PET scan; (5) Cohort comprised of non-demented people living with DS (age 35 – 50 years) and Abeta pathology confirmed by PET scan

Active immunotherapy: a new class of treatment for neurodegenerative diseases

Potential for profound social and economic impact



ACTIVE Immune Therapy for global treatment and prevention of neurodegenerative diseases

4. Achievements and key milestones 2023/24



AC Immune 2023 highlights

A year of consolidation for clinical programs

Active immunotherapy

- ACI-24.060 initial ABATE safety and immunogenicity data, and **FDA Fast Track designation**
- ACI-35.030 launched **Phase 2b trial** program, ReTain, **milestone payment received** from J&J
- ACI-7104.056 initiated **Phase 2 trial, VacSYn**, in Parkinson's disease

Pipeline

- **Wholly-owned assets advanced** towards clinical development
- Started **IND[1]-enabling studies** for mAb TDP-43 (ALS[2], FTD[3])
- Identified small molecules for *in vivo* proof-of-concept i.e. **a-syn, NLRP3**[4]

Precision Medicine

- Tau PET[5] tracer, **PI-2620, in Phase 3** clinical trial
- First a-syn[6] PET tracer paper in **Nature Communications**; next gen tracers for PD advancing
- First TDP-43[7] PET tracer presented at **AAIC'23** and advancing towards clinical testing

CMC process

- Developed CMC processes for supply of ACI-24.060 anti-Abeta active immunotherapy
- Assured supply of ACI-7104.056 anti-a-syn active immunotherapy for Phase 2

Balance Sheet strengthened

- **Cash runway extended** into 2026 with **$50 million equity financing** in December
  - *Subsequent event in 2024: further extended to **mid-2027 with Takeda's $100 million** upfront payment*

(1) Investigational New drug; (2) Amyotrophic lateral sclerosis; (3) Frontotemporal dementia; (4) (NOD)-like receptor protein; (5) Positron emission tomography; (6) alpha-synuclein; (7) TAR DNA binding protein 43

Key milestones in 2024

Multiple catalysts across pipeline

● Clinical readouts
○ Other development events

Active immunotherapies		H1	H2	
ACI-24.060 (Takeda)	Abeta		●	**Updated guidance on reporting ABATE interim results**
			●	**ABATE: Interim DS[3] data on safety and immunogenicity**
ACI-35.030 (Janssen)	pTau	○		First Patient In Phase 2b clinical trial (ReTain)
ACI-7104.056	a-syn[4]		●	**Interim safety and immunogenicity Phase 2 VacSYn clinical trial in PD[5]**
Monoclonal antibodies and small molecule drugs				
Monoclonal antibody	TDP-43[6]	○		**Completion of regulatory tox studies**
Morphomer-NLRP3	NLRP3[7]		○	**Clinical candidate declaration**
Morphomer-a-syn	a-syn		○	Lead candidate declaration
Diagnostics				
TDP-43-PET tracer	TDP-43		○	Phase 1 initiation
a-syn-PET tracer (ACI-15916)	a-syn		○	**PD candidate, IND[9]-enabling studies completed**

(1) Alzheimer's disease; (2) Positron emission tomography; (3) Down syndrome; (4) alpha-synuclein; (5) Parkinson's disease; (6) TAR DNA-binding protein 43; (7) (NOD)-like receptor protein; (8) Clinical trial application; (9) Investigational new drug

5. Financial figures



2023 Financial Overview

Key financial data (IFRS)

For the year ended December 31,	2023	2022	Change (in CHF million) (except per share data)
Revenues	14.8	3.9	10.9
R&D expenses	(54.6)	(60.3)	5.7
G&A expenses	(15.3)	(15.8)	0.5
Other operating income	1.5	1.3	0.1
Finance result, net	(0.6)	0.1	(0.7)
Total Operating expenses	**68.4**	**74.8**	**6.4**
IFRS loss for the period	**(54.2)**	**(70.8)**	**16.5**
IFRS EPS – basic and diluted	(0.64)	(0.85)	0.2

As of December 31,	2023	2022	Change (in CHF million)
Cash and cash equivalents	78.5	31.6	46.9
Short-term financial assets	24.6	91.0	(66.4)
Total liquidity[1]	**103.0**	**122.6**	**(19.5)**
Total shareholder's equity	160.6	169.0	(8.3)

(1) Liquidity is defined as the cash and cash equivalents plus short-term financial assets. These short-term financial assets are cash held in fixed-term deposits ranging in maturity from 3–12 months

AC Immune financial position

Value-driven cash management

Cash of **CHF 104.8 million**[1]
plus $100 million upfront from Takeda

2024 annual cash burn guidance
CHF 65m – 75m

Strong Balance Sheet[2]
3-year cash runway

Prudent investment strategy focused on major value drivers and near-term catalysts

(1) As of March 31, 2024; (2) Assumes second ACI-35.030 milestone payment of CHF 25m received in 2025, no other milestones or deals included.

AC Immune strong track record in deals[1] with leading pharma companies

Strategy: optimize value to risk ratio and retain significant upside

Program	Phase	Total value[2]	Upfront[2]	Milestones received[2]	Royalties %	Partner
ACI-24.060 (anti-Abeta active immunotherapy)	Phase 1b/2	>USD 2,100	USD 100		Mid-to-high teens	Takeda
ACI-35.030 (anti-pTau active immunotherapy)	Phase 2b	CHF 500	CHF 26	CHF 20	Low-double digits to mid-teens	janssen
Tau Morphomer® (small molecule drugs)	Phase 1 [6]	CHF 1,860	CHF 80 +USD 50 [7]	CHF 40	Low-double digits to mid-teens	Lilly
PI-2620 (Tau PET[4] tracer)	Phase 3 [5]	EUR 160	EUR 0.5	EUR 7	Mid-single digits to low-teens	Life Molecular Imaging
Other (concluded collaborations)		CHF 121 [3]	CHF 41	CHF 80		
Total (millions)[8]		**CHF ~4,750**	**CHF 255.2 [9]**	**CHF 147.4**		

- Outstanding potential milestone payments exceed ~CHF 4.3 billion

(1) Disclosure limited due to confidentiality agreements with collaboration partners; (2) In millions; (3) Total payments received from partner until conclusion of agreement; (4) Positron emission tomography; (5) In Alzheimer's disease; (6) Phase 1 completed; (7) Equity investment; (8) Converted to CHF on date of receipt; (9) Excludes convertible note agreement of USD 50 million

AC Immune technology platforms driving validating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

Platform				
Program	ACI-24.060	ACI-35.030	Mor Tau	Tau PET
Partner	Takeda	janssen	Lilly	Life Molecular Imaging

- An integrated approach to Central Nervous System (CNS)-specific therapies

6. Summary and Strategic outlook



Creating the future of Precision Medicine in neurodegeneration

The foundation for early detection and treatment

ACTIVE Immune Therapy

Advance clinical-stage active immunotherapies

Targeted active immunotherapies:

- **ACI-24.060** (Takeda)[1]
- **ACI-35.030** (Janssen J&J)[2]
- **ACI-7105.056** (wholly-owned)[3]

Valorize pioneering technology platforms

SupraAntigen® & Morphomer®

- Clinical entry of a-syn[4] and TDP-43[5] PET[6] tracers
- Clinical candidates for NLRP3[7] inhibitors for CNS[8] and non-CNS indications

Strong financial position

Operating capital foundation:

- Equity markets:
  - follow-on financing Dec 2023
- Partner payments:
  - Janssen ACI-35.030 milestones
  - Takeda ACI-24.060 upfront

3-year cash runway permits achievement of key milestones & execution of value-generating innovation

(1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha-synuclein; (5) TAR DNA-binding protein 43; (6) Positron emission tomography; (7) (NOD)-like receptor protein 3; (8) Central nervous system

AC Immune: Pioneering science and precision medicine

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention

Agenda items and proposals of the Board of Directors



Agenda item 1

2023 IFRS Consolidated Financial Statements, 2023 Statutory Financial Statements and 2023 Compensation Report

1.1 Approval of 2023 IFRS Consolidated Financial Statements and 2023 Statutory Financial Statements

- The Board of Directors proposes that the 2023 IFRS Consolidated Financial Statements and the 2023 Statutory Financial Statements be approved

Agenda item 1

2023 IFRS Consolidated Financial Statements, 2023 Statutory Financial Statements and 2023 Compensation Report

1.2 Advisory vote on the 2023 Compensation Report

- The Board of Directors proposes that the 2023 Compensation Report be endorsed (non-binding advisory vote)

Agenda item 2

Appropriation of Losses

- The Board of Directors proposes the following appropriation of losses:

	In CHF K
Accumulated profit (loss) at Jan 1, 2023	(262,115)
Net profit (loss) for the year 2023	(48,883)
Accumulated losses brought forward	(310,998)

Under IFRS accounting standards, the consolidated net loss for the business year 2023 amounted to CHF 54,233K

Agenda item 3

Discharge of the Members of the Board of Directors and the Executive Committee

- The Board of Directors proposes that all Members of the Board of Directors and the Executive Committee be granted discharge for the financial year 2023

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Committee

4.1 Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2024 to the AGM 2025

- The Board of Directors proposes the approval of the total maximum amount of compensation for the Members of the Board of Directors of CHF 883K (excluding employer social security contributions) covering the period from the AGM 2024 to the AGM 2025.

Agenda item 4

Compensation for the Members of the Board of Directors and the Executive Committee

4.2 Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2025

- The Board of Directors proposes the approval of the total maximum compensation for the Members of the Executive Committee with maximum value of CHF 7,605K (excluding employer social security) from 1 January 2025 to 31 December 2025.

Agenda item 5

Re-elections

5.1 Re-election of Members of the Board of Directors

- The Board of Directors proposes that each of the following persons be re-elected for a term of office until the end of the Annual General Meeting 2025:
  - Douglas Williams as Member and Chair of the Board of Directors

And as Members of the Board of Directors:

- Monika Bütler
- Carl June
- Werner Lanthaler
- Andrea Pfeifer
- Monica Shaw
- Roy Twyman

Agenda item 5

Re-elections

5.2 Re-election of Members of the Compensation, Nomination and Corporate Governance Committee

- The Board of Directors proposes that:
  - Monika Bütler
  - Roy Twyman
  - Douglas Williams

  be re-elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term of office until the end of the Annual General Meeting 2025

Agenda item 5

Re-elections

5.3 Re-election of the Statutory Auditors

- The Board of Directors proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re-elected as Statutory Auditors for the financial year 2024

Agenda item 5

Re-elections

5.4 Re-election of the Independent Proxy

- The Board of Directors proposes that Reymond & Associés, Lausanne, be re-elected as Independent Proxy for a term of office until the end of the Annual General Meeting 2025

Agenda item 6

Changes in the Articles of Association

- The Board of Directors has withdrawn its proposals for agenda items 6.1, 6.2, and 6.3.
- The Board of Directors therefore now submits to the approval by the shareholders proposal 6.4 regarding the amendments of the Articles of Association which are set out and explained in Annex 1 to the AGM 2024 Invitation "Proposals for revisions of AC Immune SA's Articles of Association" and the text of the Articles of Association available on the Company's website at: ir.acimmune.com/events/agm

Agenda item 6

Changes in the Articles of Association

6.4 Other changes

- The Board of Directors proposes to change the following Articles as reflected in Annex 1 to the AGM 2024 Invitation and the text of the Articles of Association available on the Company's website at: ir.acimmune.com/events/agm:
  - Article 6 para. 2;
  - Article 7;
  - Article 8;
  - Article 9;
  - Article 10;
  - Article 11;
  - Article 12;
  - Article 15 para. 2;
  - Article 17 paras. 2 and 3;
  - Article 18 paras. 2-4;
  - Article 20 para. 2;
  - Article 21;
  - Article 23 para. 1;
  - Article 26;
  - Article 28;
  - Article 29 paras. 1, 3 and 5;
  - Article 30;
  - Article 32 para. 2;
  - Article 33;
  - Article 37;
  - Article 38;
  - Article 39;
  - Article 40 para. 1;
  - Article 41;
  - Article 46 para. 2; and
  - Article 47

We thank you for your attendance and your continued support.